Health

Laekna Launched the new domain name www.laekna.com

SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct or indirect subsidiaries, including Laekna Therapeutics Shanghai Co., Ltd.), an emerging innovative biotech based inChina's "Zhangjiang Pharma Valley" andNew Jersey in the U.S. and focused on devel...

2022-02-07 12:47 1478

Genesis MedTech Acquires JC Medical, Creates New Structural Heart Franchise

SINGAPORE, Feb. 4, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a  structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment ...

2022-02-05 08:00 4039

Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report

SYDNEY, Feb. 4, 2022 /PRNewswire/ -- Novotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10 CRO in the2021 CenterWatch Global Site Relationship Benchmark Survey. Report available here

2022-02-04 19:47 3501

New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine

Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...

2022-02-04 06:54 2458

USANA's Malaysia and Korea markets start 2022 with major honors

SALT LAKE CITY, Feb. 4, 2022 /PRNewswire/ -- USANA's international markets have started off the new year with two major awards. USANA Korea was presented the 'family-friendly company' certification selected by the Ministry of Gender Equality and Family, whileCitta Bella Magazine awarded USANA Mal...

2022-02-04 03:00 2654

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology

SEOUL, South Korea, Feb. 3, 2022 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it had reached an agreement with TheScripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps...

2022-02-03 22:00 1736

Formus Labs Raises $5 Million to Automate Orthopedic Surgery Planning; Partners With Zimmer Biomet to Supercharge Global Launch

Formus combines AI and biomechanics to empower orthopedic surgeons with fully interactive 3D models to optimize the preoperative planning process AUCKLAND, New Zealand, Feb. 3, 2022 /PRNewswire/ -- Formus Labs, the world's first automated 3D planner for joint replacement surgeries, today announce...

2022-02-03 03:00 2753

Relationships are Messy: American Couples' Happiness Hinges on an Equal Division of Household Chores

HONG KONG, Feb. 2, 2022 /PRNewswire/ -- The pandemic has wreaked havoc on nearly every aspect of American life, including the tidiness of one's home. However, one thing remains clear: sharing household chores is a powerful love language for couples that could be the key to spicing things up in th...

2022-02-02 22:25 1449

LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS

REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, Mass., Feb. 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized cli...

2022-02-01 22:50 2087

Holmusk Enters into Collaboration with Metrocare Services

NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest real-world evidence (RWE) platform for behavioral health, has signed an agreement with Metrocare Services based inDallas, Texas on the use of real-world data to...

2022-02-01 22:00 2057

Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial

SYDNEY, Feb. 1, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has completed cohort 1 and advanced to cohort 2 in the64Cu...

2022-02-01 21:58 1421

New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good

TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...

2022-02-01 21:00 2069

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...

2022-01-31 19:00 1618

AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL

HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and Ivonescimab (PD-1/VEGF bi-specific antibody, research and devel...

2022-01-31 10:14 2113

AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the first patient was dosed in a Phase III registrational clinical trial of the Company's novel immuno-oncology drug, Ivonescimab (PD-1/VEGF bi-specific antibody, AK112), combined with chemotherapy versus placebo combin...

2022-01-31 09:51 2009

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed aUS$40 million Series A financing to advance the preclinical and clinical develop...

2022-01-29 11:37 6642

MMTEC, Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

BEIJING, Jan. 28, 2022 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), aChina-based technology company that provides access to the U.S. financial markets, today announced that onJanuary 26, 2022,t he Company received a notification letter (the "Notification Lett...

2022-01-29 06:00 6328

Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

* Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will ...

2022-01-28 22:00 6040

CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA

NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for t...

2022-01-28 22:00 2730

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qian...

2022-01-28 21:00 2429
1 ... 163164165166167168169 ... 273